Clinical Trial Update: Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/2 trial assessed belinostat (PXD101) in combination with idarubicin for patients with acute myeloid leukemia not eligible for standard intensive th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BELEODAQ (BELINOSTAT)
• Idarubicin (idarubicin)

Snippet

Sponsor: Valerio Therapeutics | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-11-13